A photo of Christine Phillips.

Christine L. Phillips, MD


  • Director, CAR T and Immunotherapy
  • Associate Professor, UC Department of Pediatrics

About

Biography

Christine Phillips, MD, is an oncologist with a clinical focus on leukemia and lymphoma and a clinical and translational research focus on the development of novel therapies for pediatric leukemia and in leukemia pharmacogenetics.

Dr. Phillips earned her undergraduate degree in biochemistry and her medical degree from Indiana University, completed her residency in pediatrics at Children’s Memorial Hospital in Chicago, and her fellowship in pediatric hematology/oncology at Cincinnati Children’s, where she was co-chief fellow. She was a 2008 Hyundai Hope on Wheels Foundation Scholar.

Insurance Information

Cincinnati Children's strives to accept a wide variety of health plans. Please contact your health insurance carrier to verify coverage for your specific benefit plan.

View Insurance Information

Publications

Disease Burden Affects Outcomes in Pediatric and Young Adult B-Cell Lymphoblastic Leukemia After Commercial Tisagenlecleucel: A Pediatric Real-World Chimeric Antigen Receptor Consortium Report. Schultz, LM; Baggott, C; Prabhu, S; Pacenta, HL; Phillips, CL; Rossoff, J; Stefanski, HE; Talano, JA; Moskop, A; Margossian, SP; et al. Journal of Clinical Oncology. 2022; 40:945-955.

Tisagenlecleucel outcomes in relapsed/refractory extramedullary ALL: a Pediatric Real World CAR Consortium Report. Fabrizio, VA; Phillips, CL; Lane, A; Baggott, C; Prabhu, S; Egeler, E; Mavroukakis, S; Pacenta, H; Rossoff, J; Stefanski, HE; et al. Blood Advances. 2022; 6:600-610.

Pooled safety analysis of tisagenlecleucel in children and young adults with B cell acute lymphoblastic leukemia. Levine, JE; Grupp, SA; Pulsipher, MA; DIetz, AC; Rives, S; Myers, GD; August, KJ; Verneris, MR; Buechner, J; Laetsch, TW; et al. Journal for ImmunoTherapy of Cancer. 2021; 9.

Treatment of posttransplant lymphoproliferative disorder with poor prognostic features in children and young adults: Short-course EPOCH regimens are safe and effective. Rubinstein, JD; Shah, R; Breese, EH; Burns, KC; Mangino, JL; Norris, RE; Lee, L; Mizukawa, B; O'Brien, MM; Phillips, CL; et al. Pediatric Blood and Cancer. 2021; 68.

Novel Treatment of Infant With COVID-19 With the Sialidase Fusion Protein, DAS181. Danziger-Isakov, L; Khalil, N; Divanovic, A; Frenck, R; Grimley, M; Iliopoulos, I; Marsh, R; Paulsen, G; Phillips, CL; Schulert, G; et al. Pediatric Infectious Disease Journal. 2021; 40:e234-e235.

Hyperdiploid Precursor B-acute Lymphoblastic Leukemia Presenting as a Cavernous Sinus Mass in a 4-Year-old Male. Sabulski, A; Bartlett, AL; Koch, BL; Vatner, R; Mizukawa, B; Phillips, CL. Journal of Pediatric Hematology/Oncology. 2021; 43:e494-e497.

Use of CD19-directed CAR T-Cell Therapy in an Infant With Refractory Acute Lymphoblastic Leukemia. Breese, EH; Krupski, C; Nelson, AS; Perentesis, JP; Phillips, CL. Journal of Pediatric Hematology/Oncology. 2021; 43:152-154.

Hyperdiploid Precursor B-acute Lymphoblastic Leukemia Presenting as a Cavernous Sinus Mass in a 4-Year-old Male. Sabulski, A; Bartlett, AL; Koch, BL; Vatner, R; Mizukawa, B; Phillips, CL. Journal of Pediatric Hematology/Oncology. 2021; 43:e494-e497.

149 Evaluating Efficacy and Safety of Tisagenlecleucel Reinfusion Following Loss of B-Cell Aplasia in Pediatric and Young Adult Patients with Acute Lymphoblastic Leukemia: HESTER Phase II Study. Boyer, MW; Chaudhury, S; Davis, KL; Driscoll, TA; Grupp, S; Hermiston, M; John, S; Keating, AK; Kovacs, C; Magley, A; et al. Transplantation and cellular therapy. 2021; 27:s141-s142.

HESTER: A Phase II Study Evaluating Efficacy and Safety of Tisagenlecleucel Reinfusion in Pediatric and Young Adult Patients with Acute Lymphoblastic Leukemia Experiencing Loss of B-Cell Aplasia. Boyer, MW; Chaudhury, S; Davis, KL; Driscoll, TA; Grupp, SA; Hermiston, M; John, S; Keating, AK; Kovacs, C; Magley, A; et al. Blood. 2020; 136:23-24.

From the Blog


4 Must-Know Points About CAR T-Cell Therapy
BlogCancer and Blood Diseases

4 Must-Know Points About CAR T-Cell Therapy

By Christine Phillips, MD10/10/2017

Patient Ratings and Comments

All patient satisfaction ratings and comments are submitted by actual patients and verified by a leading independent patient satisfaction company, NRC Health. Patient identities are withheld to ensure confidentiality and privacy. Only those providers whose satisfaction surveys are administered through Cincinnati Children’s Hospital Medical Center are displayed. Click here to learn more about our survey